Drug Profile
Research programme: autoimmune disorder therapeutics - Array BioPharma/Biogen
Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Biogen
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 30 Jul 2019 Array BioPharma has been acquired by Pfizer
- 28 Jun 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 28 May 2014 Preclinical trials in Autoimmune disorders in USA (unspecified route)